Show document

A+ | A- | | SLO | ENG

Title: Vloga in napredek zdravljenja pljučnega raka z zaviralci imunskih kontrolnih točk Authors: ID Janžič, Urška (Author) Files: PDF - Presentation file, download (333,85 KB) MD5: D5A227C0BEBF17839B76C75DAD18F549   Language: Slovenian Typology: 1.02 - Review Article Organization: SFD - Slovenian Pharmaceutical Society Abstract: Zaviralci imunskih kontrolnih točk so bistveno spre menili zdravljenje pljučnega raka, ki je že historično bolezen z zelo slabo prognozo in preživetjem. Naj večji napredek je bil dosežen pri nedrobnoceličnem raku pljuč, kjer so zaviralci imunskih kontrolnih točk postali standard zdravljenja tako v prvi, kot tudi v drugi liniji. Pri drobnoceličnem raku pljuč so zaviralci imunskih kontrolnih točk prvič po desetletjih izboljšali celokupno preživetje. V prispevku so predstavljeni mehanizmi delovanja zaviralcev imunskih kontrolnih točk ter ključne klinične študije, ki so dokazale iz boljšanje celokupnega preživetja ob zdravljenju z njimi. Publication status: Published Publication version: Version of Record Publication date: 01.05.2026 Year of publishing: 2026 Number of pages: str. 139-145 Numbering: Letn. 77, št. 2 PID: 20.500.12556/DiRROS-31044  UDC: 616.24-006:615.277 ISSN on article: 2536-4316 COBISS.SI-ID: 280073475  Note: Nasl. z nasl. zaslona; Opis vira z dne 2. 6. 2026; Publication date in DiRROS: 10.07.2026 Views: 100 Downloads: 40 Metadata:    Cite this work Plain text BibTeX EndNote XML EndNote/Refer RIS ABNT ACM Ref AMA APA Chicago 17th Author-Date Harvard IEEE ISO 690 MLA Vancouver : Copy citation

Share: Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:	Farmacevtski vestnik : strokovno glasilo slovenske farmacije
Publisher:	Slovensko farmacevtsko društvo
ISSN:	2536-4316
COBISS.SI-ID:	288686336

Licences

License:	CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:	http://creativecommons.org/licenses/by-nc/4.0/
Description:	A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:	01.01.2025

Secondary language

Language:	English
Title:	Role and advances of lung cancer treatment with immune checkpoint inhibitors
Abstract:	Immune checkpoint inhibitors have significantly transformed the treatment of lung cancer that has historically been a poor prognosis disease. The greatest progress has been achieved in non-small cell lung cancer, where immune checkpoint inhibi tors are now the standard treatment in first-line and second-line therapy. In small cell lung cancer, im mune checkpoint inhibitors have achieved the first meaningful survival improvement in decades. This article summarizes mechanisms of action and key clinical trials that have exhibited improved survival in lung cancer patients.

Back